• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email
    SC 13G/A 1 o213240sc13ga3.htm AMENDMENT NO. 3

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 3) *

     

     

     

    InMode Ltd.

    (Name of Issuer)

     

    Ordinary Shares, par value NIS 0.01 per share

    (Title of Class of Securities)

     

    M5425M 103

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

     

    o Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    ______________________________

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     

     

     

      
     

     

    CUSIP No. M5425M 103

     

    1.

    NAME OF REPORTING PERSON

     

    BoomerangFX International SRL

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       o

    (b)       o

     

    3. SEC USE ONLY:
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Barbados

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER:

     

    0 shares

    6.

    SHARED VOTING POWER:

     

    0 shares

    7.

    SOLE DISPOSITIVE POWER:

     

    0 shares

    8.

    SHARED DISPOSITIVE POWER:

     

    0 shares

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    0 shares

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):  o
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    0.0%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    CO

     

     Page 2 of 10 
     

     

    CUSIP No. M5425M 103

     

    1.

    NAME OF REPORTING PERSON

     

    I.V.C. Enterprises SRL

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       o

    (b)       o

     

    3. SEC USE ONLY:
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Barbados

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER:

     

    0 shares

    6.

    SHARED VOTING POWER:

     

    0 shares

    7.

    SOLE DISPOSITIVE POWER:

     

    0 shares

    8.

    SHARED DISPOSITIVE POWER:

     

    0 shares

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    0 shares

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): o
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    0.0%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    CO

     

     Page 3 of 10 
     

     

    CUSIP No. M5425M 103

     

    1.

    NAME OF REPORTING PERSON

     

    DRM2 Investments SRL

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       o

    (b)       o

     

    3. SEC USE ONLY:
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Barbados

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER:

     

    0 shares

    6.

    SHARED VOTING POWER:

     

    0 shares

    7.

    SOLE DISPOSITIVE POWER:

     

    0 shares

    8.

    SHARED DISPOSITIVE POWER:

     

    0 shares

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    0 shares

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): o
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    0.0%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    CO

     

     Page 4 of 10 
     

     

    CUSIP No. M5425M 103

     

    1.

    NAME OF REPORTING PERSON

     

    Dr. Stephen Mulholland

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       o

    (b)       o

     

    3. SEC USE ONLY:
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Canada

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER:

     

    2,971,193 shares

    6.

    SHARED VOTING POWER:

     

    0 shares

    7.

    SOLE DISPOSITIVE POWER:

     

    2,971,193 shares

    8.

    SHARED DISPOSITIVE POWER:

     

    0 shares

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    2,971,193 shares

    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): o
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    3.54%(1)

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

     

    (1) Based on 83,982,462 ordinary shares outstanding as of December 31, 2023 reported on the Issuer’s annual report on Form 20-F filed with the Securities and Exchange Commission on February 13, 2024.

     

     Page 5 of 10 
     

     

    CUSIP No. M5425M 103

     

    Item 1.

     

    (a)Name of Issuer:

     

    InMode Ltd. (the “Issuer”).

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    Tavor Building, Sha’ar Yokneam

    P.O. Box 533

    Yokneam 2069206, Israel

     

    Item 2.

     

    (a)Name of Person Filing:

     

    This filing is being made jointly by BoomerangFX International SRL (“BoomerangFX”), I.V.C. Enterprises SRL (“I.V.C.”), DRM2 Investments SRL (formerly NEV Property Investments SRL) (“DRM2”) and Dr. Stephen Mulholland (“Dr. Mulholland”), each of whom is sometimes referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    BoomerangFX is a Barbados society with restricted liability and a wholly owned direct subsidiary of I.V.C., which is a Barbados society with restricted liability and a wholly owned direct subsidiary of DRM2, a Barbados society with restricted liability. DRM2 is wholly owned by Dr. Mulholland. The ordinary shares of the Issuer as to which beneficial ownership is reported herein are owned directly by Dr. Mulholland, and DRM2, I.V.C. and BoomerangFX are not beneficial owners of the ordinary shares.

     

    (b)Address of Principal Business Office or, if none, Residence:

     

    BoomerangFX International SRL

    No. 15 Maxwell Main Road
    Christ Church, Barbados BB15042

     

    I.V.C. Enterprises SRL
    No. 15 Maxwell Main Road
    Christ Church, Barbados BB15042

     

    DRM2 Investments SRL
    No. 15 Maxwell Main Road
    Christ Church, Barbados BB15042

     

    Dr. Stephen Mulholland

    c/o BoomerangFX International SRL
    No. 15 Maxwell Main Road
    Christ Church, Barbados BB15042

     

     Page 6 of 10 
     

     

    CUSIP No. M5425M 103

     

    (c)Citizenship:

     

    BoomerangFX is organized under the laws of Barbados.

     

    I.V.C. is organized under the laws of Barbados.

     

    DRM2 is organized under the laws of Barbados.

     

    Dr. Mulholland is a citizen of Canada.

     

    (d)Title of Class of Securities:

     

    Ordinary shares, NIS 0.01 par value per share

     

    (e)CUSIP Number:

     

    M5425M 103

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

    (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b) (1)(ii)(F);

     

    (g) o A parent holding company or control person in accordance with §240.13d-1(b) (1)(ii)(G);

     

    (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) o Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable.

     

     Page 7 of 10 
     

     

    CUSIP No. M5425M 103

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

      A. BoomerangFX International SRL
        (a) Amount beneficially owned:  -0-
        (b) Percent of class: 0.0%
        (c) (i) Sole power to vote or direct the vote:  -0-
          (ii) Shared power to vote or direct the vote:  -0-
          (iii) Sole power to dispose or direct the disposition of:  -0-
          (iv) Shared power to dispose or direct the disposition of:  -0-

     

     

      B. I.V.C. Enterprises SRL
        (a) Amount beneficially owned:  -0-
        (b) Percent of class: 0.0%
        (c) (i) Sole power to vote or direct the vote:  -0-
          (ii) Shared power to vote or direct the vote:  -0-
          (iii) Sole power to dispose or direct the disposition of:  -0-
          (iv) Shared power to dispose or direct the disposition of:  -0-

     

     

      C. DRM2 Investments SRL
        (a) Amount beneficially owned:  -0-
        (b) Percent of class: 0.0%
        (c) (i) Sole power to vote or direct the vote:  -0-
          (ii) Shared power to vote or direct the vote:  -0-
          (iii) Sole power to dispose or direct the disposition of:  -0-
          (iv) Shared power to dispose or direct the disposition of:  -0-

     

     

      D. Dr. Stephen Mulholland
        (a) Amount beneficially owned:  2,971,193
        (b) Percent of class: 3.54%. This percentage is calculated based on 83,982,462 ordinary shares outstanding as of December 31, 2023 reported on the Issuer’s annual report on Form 20-F filed with the Securities and Exchange Commission on February 13, 2024.
        (c) (i) Sole power to vote or direct the vote:  2,971,193
          (ii) Shared power to vote or direct the vote:   -0-
          (iii) Sole power to dispose or direct the disposition of:  2,971,193
          (iv) Shared power to dispose or direct the disposition of:  -0-

     

     Page 8 of 10 
     

     

    CUSIP No. M5425M 103

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    Not applicable.

     

     Page 9 of 10 
     

     

    CUSIP No. M5425M 103

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 8, 2024

     

     

    BOOMERANGFX INTERNATIONAL SRL

     

    /s/ Neal Griffith

     

    Name: Neal Griffith

    Title: Manager

     

     

    DR. STEPHEN MULHOLLAND

     

    /s/ Dr. Stephen Mulholland

     

    Name: Dr. Stephen Mulholland

     

       
     

    I.V.C. ENTERPRISES SRL

     

    /s/ Neal Griffith

     

    Name: Neal Griffith

    Title: Manager

     

       
     

    DRM2 INVESTMENTS SRL

     

    /s/ Neal Griffith

     

    Name: Neal Griffith

    Title: Manager

     

     

    Page 10 of 10

     

     

     

    Get the next $INMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • InMode downgraded by BTIG Research

      BTIG Research downgraded InMode from Buy to Neutral

      4/29/25 8:06:22 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

      4/28/25 1:56:11 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BTIG Research initiated coverage on InMode with a new price target

      BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

      10/17/24 7:41:34 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025

      YOKNEAM, Israel, May 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated May 9, 2025. The letter can be viewed here The full text of the letter follows: May 28, 2025 Mr. Pedro EscuderoCEO and CIODOMA, Perpetual Capital Management LLC Dear Mr. Escudero, This letter is in response to your letter dated May 9, 2025. First, I would like to thank you for voting for me to be re-elected to the Board of Directors. I really appreciate your vote of confidence and trust. I unde

      5/28/25 8:30:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode Announces Health Canada Certification of the IgniteRF Platform with the New QuantumRF Technology

      YOKNEAM, Israel, May 20, 2025 /CNW/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, is pleased to announce Health Canada certification of IgniteRF, an advanced platform offering a comprehensive suite of minimally invasive radiofrequency solutions for the face and body.     IgniteRF is equipped with nine proprietary technologies, including the new QuantumRF, Morpheus8 Burst and Burst Deep, BodyTite Turbo, and FaceTite Turbo handpieces. This advanced complement of technologies leverages the heritage and efficacy of clinically proven bipolar radiofrequency to address consumer demand for minimal downtime procedures that deliver natural-looking results

      5/20/25 9:17:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

      Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI, May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.  The letter can be downloaded here The full text of the letter follows: May 9th, 2025 To the Board Members of InMode: For over a year, we have communicated p

      5/9/25 8:22:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    SEC Filings

    See more
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      5/19/25 7:00:11 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      4/28/25 7:00:06 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      4/3/25 7:07:38 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Financials

    Live finance-specific insights

    See more
    • DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

      Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI, May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.  The letter can be downloaded here The full text of the letter follows: May 9th, 2025 To the Board Members of InMode: For over a year, we have communicated p

      5/9/25 8:22:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease

      In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares  YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Quarterly GAAP revenues of $77.9 million, compared to $80.3 million in the first quarter of 2024.Quarterly revenues from consumables and service of $20.2 million, a decrease of 10% compared to the first quarter of 2024.GAAP operating income of $15.6 million, *non-GAAP operating income of $18.1 million.Total cash position of $512.9 million as

      4/28/25 7:00:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode to Report First Quarter 2025 Financial Results and Hold Conference Call on April 28, 2025, Expects Q1 Revenue Between $77.2M-$77.5M, Reiterates FY 2025 Revenue Guidance Between $395M-$405M

      Conference call to be held on Monday, April 28, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 14, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2025 before the Nasdaq market opens on Monday, April 28, 2025. InMode is currently finalizing its financial results for the first quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

      4/14/25 7:00:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

      SC 13G/A - InMode Ltd. (0001742692) (Subject)

      2/13/24 4:31:18 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

      SC 13G/A - InMode Ltd. (0001742692) (Subject)

      2/13/24 4:25:40 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by InMode Ltd.

      SC 13G - InMode Ltd. (0001742692) (Subject)

      2/6/24 9:36:39 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care